Iovance Biotherapeutics, Inc. Common Stock (IOVA) Ownership & Trading Activity
Institutional holders, insider transactions, and congressional trades for IOVA. 13F holdings as of 2026-09-30.
In 13F filings for the quarter ended September 30, 2026, 255 institutions reported holding IOVA, with 175.8 million shares worth $2.6 billion in aggregate.
Top Institutional Holders
| Institution | Shares | Value | Change |
|---|---|---|---|
| BlackRock | 37,903,960 | $562M | INCREASED |
| Vanguard | 33,907,351 | $503M | DECREASED |
| State Street | 21,695,003 | $322M | DECREASED |
| Geode Capital Management | 10,452,242 | $155M | INCREASED |
| Dimensional Fund Advisors | 6,238,693 | $92M | DECREASED |
Recent Insider Trades
| Insider | Type | Shares | Value | Date |
|---|---|---|---|---|
| Frederick G Vogt (Interim CEO & General Counsel) | EXERCISE | 200,000 | $2M | 2026-11-11 |
| Frederick G Vogt (Interim CEO & General Counsel) | TAX-W | 191,303 | $2M | 2026-11-11 |
| Frederick G Vogt (Interim CEO & General Counsel) | EXERCISE | 200,000 | $2M | 2026-11-11 |
| Daniel Gordon Kirby (Chief Commercial Officer) | EXERCISE | 10,000 | 2026-11-10 | |
| Daniel Gordon Kirby (Chief Commercial Officer) | TAX-W | 3,935 | $32K | 2026-11-10 |
Full institutional holdings, insider history, and congressional trades for Iovance Biotherapeutics, Inc. Common Stock on SentiSense.